Advanced thyroid cancers: new era of treatment
Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with...
Gespeichert in:
| Veröffentlicht in: | Medical oncology (Northwood, London, England) London, England), 2014-07, Vol.31 (7), p.49, Article 49 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 49 |
| container_title | Medical oncology (Northwood, London, England) |
| container_volume | 31 |
| creator | Mohammed, Amrallah A. EL-Shentenawy, Ayman |
| description | Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment. |
| doi_str_mv | 10.1007/s12032-014-0049-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1542292127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3359895251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-82fc586ad8b1a7281d141bf69b4ef4e3d0cc38bc4273f67b58ad40f79597b5a43</originalsourceid><addsrcrecordid>eNp1kEtLw0AQxxdRbK1-AC8S8Lx1Zh9J1lspvqDgRcHbstmHttik7qbafntTUsWLp5lh_g_4EXKOMEaA4iohA84ooKAAQtHNARmilIoix5fDbueyoCBzGJCTlBYADCVTx2TAhIIScjkk44n7NLX1LmvftrGZu8zuzpius9p_ZT6arAlZG71pl75uT8lRMO_Jn-3niDzf3jxN7-ns8e5hOplRywvW0pIFK8vcuLJCU7ASHQqsQq4q4YPw3IG1vKysYAUPeVHJ0jgBoVBSdYcRfEQu-9xVbD7WPrV60axj3VVqlIIxxbCzjgj2KhublKIPehXnSxO3GkHvCOmekO4I6R0hvek8F_vkdbX07tfxg6QTsF6Qulf96uOf6n9TvwF16m_O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1542292127</pqid></control><display><type>article</type><title>Advanced thyroid cancers: new era of treatment</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mohammed, Amrallah A. ; EL-Shentenawy, Ayman</creator><creatorcontrib>Mohammed, Amrallah A. ; EL-Shentenawy, Ayman</creatorcontrib><description>Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-014-0049-x</identifier><identifier>PMID: 24908065</identifier><identifier>CODEN: MONCEZ</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Anilides - adverse effects ; Anilides - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Boronic Acids - pharmacology ; Bortezomib ; Cell Differentiation - drug effects ; Cell Proliferation - drug effects ; ErbB Receptors - antagonists & inhibitors ; Genetic Therapy - methods ; Hematology ; Histone Deacetylase Inhibitors - pharmacology ; Humans ; Immunotherapy - methods ; Internal Medicine ; Lithium - pharmacology ; Medicine ; Medicine & Public Health ; Molecular Targeted Therapy - methods ; Oncology ; Pathology ; Piperidines - adverse effects ; Piperidines - therapeutic use ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrazines - pharmacology ; Pyridines - adverse effects ; Pyridines - therapeutic use ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; Review Article ; Stilbenes - pharmacology ; Thalidomide - pharmacology ; Thyroid Neoplasms - drug therapy ; Thyroid Neoplasms - metabolism ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - therapy</subject><ispartof>Medical oncology (Northwood, London, England), 2014-07, Vol.31 (7), p.49, Article 49</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-82fc586ad8b1a7281d141bf69b4ef4e3d0cc38bc4273f67b58ad40f79597b5a43</citedby><cites>FETCH-LOGICAL-c372t-82fc586ad8b1a7281d141bf69b4ef4e3d0cc38bc4273f67b58ad40f79597b5a43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-014-0049-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-014-0049-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24908065$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohammed, Amrallah A.</creatorcontrib><creatorcontrib>EL-Shentenawy, Ayman</creatorcontrib><title>Advanced thyroid cancers: new era of treatment</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.</description><subject>Anilides - adverse effects</subject><subject>Anilides - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Boronic Acids - pharmacology</subject><subject>Bortezomib</subject><subject>Cell Differentiation - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>Genetic Therapy - methods</subject><subject>Hematology</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Immunotherapy - methods</subject><subject>Internal Medicine</subject><subject>Lithium - pharmacology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - therapeutic use</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazines - pharmacology</subject><subject>Pyridines - adverse effects</subject><subject>Pyridines - therapeutic use</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>Review Article</subject><subject>Stilbenes - pharmacology</subject><subject>Thalidomide - pharmacology</subject><subject>Thyroid Neoplasms - drug therapy</subject><subject>Thyroid Neoplasms - metabolism</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - therapy</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kEtLw0AQxxdRbK1-AC8S8Lx1Zh9J1lspvqDgRcHbstmHttik7qbafntTUsWLp5lh_g_4EXKOMEaA4iohA84ooKAAQtHNARmilIoix5fDbueyoCBzGJCTlBYADCVTx2TAhIIScjkk44n7NLX1LmvftrGZu8zuzpius9p_ZT6arAlZG71pl75uT8lRMO_Jn-3niDzf3jxN7-ns8e5hOplRywvW0pIFK8vcuLJCU7ASHQqsQq4q4YPw3IG1vKysYAUPeVHJ0jgBoVBSdYcRfEQu-9xVbD7WPrV60axj3VVqlIIxxbCzjgj2KhublKIPehXnSxO3GkHvCOmekO4I6R0hvek8F_vkdbX07tfxg6QTsF6Qulf96uOf6n9TvwF16m_O</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Mohammed, Amrallah A.</creator><creator>EL-Shentenawy, Ayman</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20140701</creationdate><title>Advanced thyroid cancers: new era of treatment</title><author>Mohammed, Amrallah A. ; EL-Shentenawy, Ayman</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-82fc586ad8b1a7281d141bf69b4ef4e3d0cc38bc4273f67b58ad40f79597b5a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anilides - adverse effects</topic><topic>Anilides - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Boronic Acids - pharmacology</topic><topic>Bortezomib</topic><topic>Cell Differentiation - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>Genetic Therapy - methods</topic><topic>Hematology</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Immunotherapy - methods</topic><topic>Internal Medicine</topic><topic>Lithium - pharmacology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - therapeutic use</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazines - pharmacology</topic><topic>Pyridines - adverse effects</topic><topic>Pyridines - therapeutic use</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>Review Article</topic><topic>Stilbenes - pharmacology</topic><topic>Thalidomide - pharmacology</topic><topic>Thyroid Neoplasms - drug therapy</topic><topic>Thyroid Neoplasms - metabolism</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohammed, Amrallah A.</creatorcontrib><creatorcontrib>EL-Shentenawy, Ayman</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohammed, Amrallah A.</au><au>EL-Shentenawy, Ayman</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced thyroid cancers: new era of treatment</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>31</volume><issue>7</issue><spage>49</spage><pages>49-</pages><artnum>49</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><coden>MONCEZ</coden><abstract>Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24908065</pmid><doi>10.1007/s12032-014-0049-x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-0560 |
| ispartof | Medical oncology (Northwood, London, England), 2014-07, Vol.31 (7), p.49, Article 49 |
| issn | 1357-0560 1559-131X |
| language | eng |
| recordid | cdi_proquest_journals_1542292127 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Anilides - adverse effects Anilides - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Boronic Acids - pharmacology Bortezomib Cell Differentiation - drug effects Cell Proliferation - drug effects ErbB Receptors - antagonists & inhibitors Genetic Therapy - methods Hematology Histone Deacetylase Inhibitors - pharmacology Humans Immunotherapy - methods Internal Medicine Lithium - pharmacology Medicine Medicine & Public Health Molecular Targeted Therapy - methods Oncology Pathology Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazines - pharmacology Pyridines - adverse effects Pyridines - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Review Article Stilbenes - pharmacology Thalidomide - pharmacology Thyroid Neoplasms - drug therapy Thyroid Neoplasms - metabolism Thyroid Neoplasms - pathology Thyroid Neoplasms - therapy |
| title | Advanced thyroid cancers: new era of treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A44%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20thyroid%20cancers:%20new%20era%20of%20treatment&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Mohammed,%20Amrallah%20A.&rft.date=2014-07-01&rft.volume=31&rft.issue=7&rft.spage=49&rft.pages=49-&rft.artnum=49&rft.issn=1357-0560&rft.eissn=1559-131X&rft.coden=MONCEZ&rft_id=info:doi/10.1007/s12032-014-0049-x&rft_dat=%3Cproquest_cross%3E3359895251%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1542292127&rft_id=info:pmid/24908065&rfr_iscdi=true |